FasCure Therapeutics LLC
Biotech · Private
Biologics combining soluble Fas ligand (SA-FasL) and IL-2 agonists to modulate T effector and T regulatory cells for transplant tolerance
- Grants
- $1.8M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a novel adjuvant system for therapeutic vaccines against lung cancer | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a novel adjuvant system for therapeutic vaccines against lung cancer | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · SA-FasL-engineered human islets as a novel product for the treatment of type 1 diabetes | $224,529 | |
| Federal grant | Department of Health and Human Services · Phase I · SA FasL engineered human islets as a novel product for the treatment of type diabetes | $224,529 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Exploiting activation-induced cell death as a means of inducing tolerance to kidney allografts | $224,999 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Exploiting activation-induced cell death as a means of inducing tolerance to kidney allografts | $224,999 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1970 | CMP TARNHELM PARTNERS, LLC | — | — |
| 1971 | VAST THERAPEUTICS, INC. | — | — |
| 1972 | Vesicor Therapeutics, Inc. | — | $715K |
| 1973 | FasCure Therapeutics LLC | — | — |
| 1974 | UBIQUITX, INC. | — | — |
| 1975 | ACCUNOVO BIOTECHNOLOGIES INC | — | — |
| 1976 | VLP THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Anti-cancer Monotherapy Using SA-4-1BBLapplication
- Anti-cancer Monotherapy Using SA-4-1BBLapplication
- Anti-cancer Monotherapy Using SA-4-1BBLapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.